Masked volume wise principal component analysis of small adrenocortical tumours in dynamic [11C]-metomidate positron emission tomography by Razifar, Pasha et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Medical Imaging
Open Access Research article
Masked volume wise principal component analysis of small 
adrenocortical tumours in dynamic [11C]-metomidate positron 
emission tomography
Pasha Razifar*1,2, Joakim Hennings3, Azita Monazzam2, Per Hellman3, 
Bengt Långström4 and Anders Sundin5,6
Address: 1Molecular Imaging & CT Research, GE Healthcare, SE-53188 Waukesha, Wisconsin, USA, 2Uppsala Applied Science Lab (UASL), GE 
Healthcare, Uppsala Sweden, 3Department of Surgery, Uppsala University Hospital, Uppsala, Sweden, 4Department of Biochemistry and Organic 
Chemistry, Uppsala, Sweden, 5Department of Radiology, Karolinska University Hospital, Stockholm, Sweden and 6Department of Radiology, 
Uppsala University Hospital, Uppsala, Sweden
Email: Pasha Razifar* - pasha.razifar@ge.com; Joakim Hennings - joakim.hennings@surgsci.uu.se; Azita Monazzam - azita.monazzam@ge.com; 
Per Hellman - per.hellman@surgsci.uu.se; Bengt Långström - bengt.langstrom@biorg.uu.se; Anders Sundin - anders.sundin@ki.se
* Corresponding author    
Abstract
Background: In previous clinical Positron Emission Tomography (PET) studies novel approaches for
application of Principal Component Analysis (PCA) on dynamic PET images such as Masked Volume Wise
PCA (MVW-PCA) have been introduced. MVW-PCA was shown to be a feasible multivariate analysis
technique, which, without modeling assumptions, could extract and separate organs and tissues with
different kinetic behaviors into different principal components (MVW-PCs) and improve the image quality.
Methods:  In this study, MVW-PCA was applied to 14 dynamic 11C-metomidate-PET (MTO-PET)
examinations of 7 patients with small adrenocortical tumours. MTO-PET was performed before and 3 days
after starting per oral cortisone treatment. The whole dataset, reconstructed by filtered back projection
(FBP) 0–45 minutes after the tracer injection, was used to study the tracer pharmacokinetics.
Results: Early, intermediate and late pharmacokinetic phases could be isolated in this manner. The MVW-
PC1 images correlated well to the conventionally summed image data (15–45 minutes) but the image noise
in the former was considerably lower. PET measurements performed by defining "hot spot" regions of
interest (ROIs) comprising 4 contiguous pixels with the highest radioactivity concentration showed a trend
towards higher SUVs when the ROIs were outlined in the MVW-PC1 component than in the summed
images. Time activity curves derived from "50% cut-off" ROIs based on an isocontour function whereby
the pixels with SUVs between 50 to 100% of the highest radioactivity concentration were delineated,
showed a significant decrease of the SUVs in normal adrenal glands and in adrenocortical adenomas after
cortisone treatment.
Conclusion: In addition to the clear decrease in image noise and the improved contrast between different
structures with MVW-PCA, the results indicate that the definition of ROIs may be more accurate and
precise in MVW-PC1 images than in conventional summed images. This might improve the precision of
PET measurements, for instance in therapy monitoring as well as for delineation of the tumour in radiation
therapy planning.
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Background
Adrenal tumours are common incidental radiological
findings in computed tomography (CT) examinations
that are performed because of non-adrenal disease. For
these adrenal tumours the term generally used is inciden-
taloma. As a result of the more frequent use and improved
spatial resolution of modern multi-detector CT scanners,
incidentalomas are being found more often. Because of
their malignancy potential and because these tumours
may cause hormonal hypersecretion, the discovery of an
incidentaloma necessitates biochemical and radiological
work-ups. Larger tumours (> 3–4 cm), tumours with high
degree of suspicion of malignancy, and hormone-hyper-
secreting lesions are surgically removed [1-5].
The initial work-up for adrenal incidentalomas is based
on laboratory testing and CT or Magnetic Resonance
Imaging (MRI) examinations or both [2,3]. However,
after CT or MRI examination or both, approximately one-
third of adrenal tumours remain uncharacterized. To
either rule out or to diagnose malignant disease, radiolog-
ical follow-up for tumour size assessment is performed
repeatedly by CT or MRI. Additional sensitive and reliable
imaging methods are therefore needed to manage the con-
siderable clinical problem to differentiate hormone-over-
producing or malignant incidentalomas or both, for
which treatment is needed, from benign non-hypersecret-
ing lesions.
In previous studies, positron emission tomography (PET)
with 11C labeled metomidate, [11C]-MTO (MTO-PET), has
been introduced as a sensitive method to determine the
adrenocortical origin of adrenal tumours [6-11]. [11C]-
MTO has a high affinity for the 11β-hydroxylase enzyme in
the adrenal cortex and MTO-PET can therefore differenti-
ate adrenocortical tumours from those of non-adrenocor-
tical origin.
Tumours larger than 1.5–2 cm and that are [11C]-MTO
positive are generally readily depicted as a rounded, usu-
ally homogenously [11C]-MTO accumulating lesion.
Detection is facilitated when the uptake in the lesion is
higher or lower than the normal adrenal cortex; however,
when the accumulation is similar in both, the tumour is
generally recognized because it distorts the normal anat-
omy of the gland. Because of technical limitations related
to camera resolution [12-14], the delineation of small
adrenal tumours, less than 1–1.5 cm, by MTO-PET seems
to be limited [7,8]. Moreover aldosterone-hypersecreting
Conn-adenomas are usually in or below this size range,
improvements are needed before PET can be used for
lesion detection in primary aldosteronism.
For characterization purposes and to achieve reliable PET
measurements of the tracer accumulation in tumours and
normal tissues, MTO-PET may be performed dynamically
with the examination started synchronously with the
tracer injection and continued for 45 minutes. By dividing
the scanning sequence into several short time frames, each
typically one to a few minutes long, the [11C]-MTO accu-
mulation in the tumour and the normal adrenal can be
determined over time. The time frames representing the
highest tracer uptake in the tumour, relative to the normal
adrenal cortex, may then be summed to a so-called
"summed image" to optimize the image reading.
Dynamic MTO-PET images from 15 to 45 minutes after
the tracer injection are typically summed to create transax-
ial images of regional radioactivity concentration. How-
ever, the summation of image data is generally performed
routinely and is not based on a pharmacokinetic analysis
of the tumour in the individual patient since such a pro-
cedure is time consuming. In addition to visualizing the
lesion, it is essential for its characterization to perform
accurate PET measurements by outlining regions/volume
of interest (ROIs/VOIs) with high precision, especially
when the tumour is small. It has previously been demon-
strated that the magnitude and variation of the noise, and
partial volume effect in the PET images might affect the
precision of defining ROIs and the resulting SUV measure-
ments [15].
In previous studies, Masked Volume Wise PCA (MVW-
PCA) was introduced [16,17]. It was shown for several
PET tracers that MVW-PCA could be used as a multivariate
analysis technique, which without any kinetic assumption
could extract and separate organs and tissues with differ-
ent kinetic behaviors into different principal components
(MVW-PCs). Moreover, MVW-PCA enhanced the image
quality by improving the visual contrast between the ana-
tomical structures thereby yielding more detailed anatom-
ical information.
The aim of the present study was to apply the introduced
MVW-PCA approach to MTO-PET examinations to obtain
diagnostic information from the whole dataset. A further
aim was to assess possible improvements in image quality
achieved by applying MVW-PCA, which might lead to
improvement of the precision when defining ROIs/VOIs
used for PET measurements in tumour and normal adre-
nal gland.
Methods
Here, MVW-PCA was applied to dynamic MTO-PET exam-
inations of the adrenals of patients with small adrenocor-
tical tumors (1–2 cm). Six of the seven patients hadBMC Medical Imaging 2009, 9:6 http://www.biomedcentral.com/1471-2342/9/6
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biochemically proven or suspected primary aldos-
teronism and one patient had a small hormonally silent
incidentaloma. MTO-PET was performed before and 3
days after starting per oral cortisone treatment. The ration-
ale behind this regimen was that possible variations in
tracer uptake might be detected in the same patient during
two different hormonal states. Moreover, each patient
could function as his or her own control. The whole data-
set, 0–45 minutes after the tracer injection, was used to
include all information about tracer pharmacokinetics to
extract and separate tissues with different kinetic behav-
iors in several uncorrelated pharmacokinetic compo-
nents. The aim was three-fold: firstly, to evaluate the early
phase of the MTO-PET sequence for additional informa-
tion and possibly better depiction of small adrenocortical
adenomas, (as compared to the visualization of these
tumours in the later phases of the examination). Sec-
ondly, to determine the different MVW-PCs in the exami-
nations and to compare the visibility of the tumours in
these components with the summed images achieved by
conventional summing of the dynamic PET sequence data
15 to 45 minutes after the tracer injection. Thirdly, to eval-
uate the SUVs in tumour and contralateral normal adrenal
gland tissue for potential differences by drawing ROIs and
including these tissues in the MVW-PCA images and the
summation images, respectively.
Tracer administration and patient data
MTO-PET of the adrenals was performed on seven
patients, three male and four female, aged 34–78 years
identified from a study performed by Hennings and co-
workers [11].
The study was approved by the local ethics committee (No
02-262) and was performedin compliance with the Hel-
sinki Declaration. Inclusion into the study was by
informed consent. Each patient had a 1- to 2-cm adreno-
cortical adenoma as characterized by CT attenuation
measurements. In addition to the initial study, MTO-PET
was performed a second time on each patient after 3 days
of per oral cortisone medication (dexametasone 0.5 mg
three times daily). The patients were examined after a
minimum of four hours of fasting, allowing free intake of
clear liquids. Approximately 10 MBq/kg of [11C]-MTO per
kilogram of body weight, corresponding to 715 ± 199
MBq (mean ± SD) range 370–1050 MBq, was adminis-
tered. After a rapid intravenous bolus injection of the
tracer, a 45-minute dynamic examination sequence was
started which comprised 14 time frames: 5 × 1 minute, 5
× 3 minutes, 3 × 5 minutes and 1 × 10 minutes.
Image analysis and PET measurements
Masked Volume Wise Principal Component Analysis
The method is based on using noise pre-normalized data
that represent the whole scanned section of each frame as
a single variable. They are applied after the background
has been removed, i.e, masked out. The MVW-PC volumes
that are generated contain organs and tissues with differ-
ent and uncorrelated kinetic behaviors of the adminis-
tered tracer, and the number of output MVW-PC volumes
is equal to the number of PET frames of the study [16].
Since no region could be used as a reference region here,
the kinetic pre-normalization was excluded from the
MVW-PCA procedure. Only the first three components
were explored since higher components contained only
noise.
Software used for the application of MVW-PCA on
dynamic PET images was developed in-house by one of
the authors (PR) using Matlab 7.2 (The Mathworks, Nat-
ick, Massachusetts) with installed statistical and image
processing toolboxes.
Region of interest
Both the summed images and the MVW-PC1 images were
used to outline ROIs representing the adrenal tumour and
the contralateral normal adrenal gland. Subsequently, 4
contiguous pixels corresponding to 0.64 cm2 with the
highest radioactivity concentrations, i.e., the "hot spot"
[18] were identified in the tumour and in the normal con-
tralateral adrenal gland, respectively. The coordinates for
the individual pixels of these hot spots were recorded and
used for calculation of SUVs.
Moreover, ROIs were defined using the isocontour func-
tion whereby the pixels with SUVs between 50 and 100%
of the highest radioactivity concentration i.e., "50% cut-
off" were delineated to outline the adrenal tumour and
the contralateral normal adrenal gland respectively.
The mean Time Activity Curves (TACs) were calculated,
plotted, and compared for ROIs delineated using the 50%
cut-off method, which represented the adrenal tumour
and the contralateral normal adrenal gland, respectively,
in both the MVW-PC1 and the summed images. Further-
more, the radioactivity concentrations in the summed
images were re-calculated to provide SUV images whereby
the radioactivity concentration (Bq/cc) was divided by the
injected dose per gram body weight.
To compare the precision by which the "hot spot" ROIs
were outlined, using the two methods, the coordinates for
the pixels representing the ROI "hotspots" in the summed
images and the MVW-PC1 images, respectively, were
imported into the corresponding SUV images. The SUVs
for the corresponding pixels were registered and the mean
SUV of the ROIs was calculated.
Statistical methods and illustrations
The mean SUV and the standard deviation of the mean
(SEM) for the defined ROIs using both "hot spot" andBMC Medical Imaging 2009, 9:6 http://www.biomedcentral.com/1471-2342/9/6
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50% cut-off methods in the summed as well as MVW-PC1
images were calculated, respectively.
A univariate regression analysis was performed in which
the SUVs obtained in ROIs defined in the MVW-PC1
images were plotted against the SUVs obtained in ROIs
defined in the summed images.
Repeated measures ANOVA based on "Bonferroni's multi-
ple comparison test", linear regression and Student's t-test
(paired and two-tailed) were performed to investigate dif-
ferences between the "hot spot" and the 50% cut-off
methods when MVW-PC1 and summed images were used
for delineation and quantification of the ROIs.
Here, Graph Pad Prism Version 4.03 (Graph Pad Software,
Inc, San Diego, USA) was used to carry out all statistical
analysis and graphical illustrations.
Table 1: Results obtained from applying one-way ANOVA to the mean SUVs using the "hot spot" method, representing 
adrenocortical adenomas and normal adrenal glands defined in MVW-PC1 and summed images, respectively.
Comparison Significant
(P < 0.001)
Mean difference
MVW-PC1, untreat, Adenoma vs MVW-PC1, treated, adenoma No 1.171
MVW-PC1, untreat, Adenoma vs MVW-PC1, untreated, normal No 6.771
SUM, untreated, adenoma vs SUM, treated, adenoma No 1.143
SUM, untreated, adenoma vs SUM, untreated, normal No 6.843
MVW-PC1, treated, adenoma vs MVW-PC1, treated, normal No 6.943
SUM, treated, adenoma vs SUM, treated, normal No 7.014
MVW-PC1, untreated, normal vs MVW-PC1, treated, normal No 1.343
SUM, untreated, normal vs SUM, treated, normal No 1.314
First Column shows the summed images generated by sum- ming images through frame 9–14 (15–45 min) and second  column shows the corresponding MVW-PC1 images gener- ated by application of MVW-PCA on the whole imaging  sequence of 0–45 minutes Figure 1
First Column shows the summed images generated 
by summing images through frame 9–14 (15–45 min) 
and second column shows the corresponding MVW-
PC1 images generated by application of MVW-PCA 
on the whole imaging sequence of 0–45 minutes. 
These are shown in the transaxial (first row) sagittal (second 
row), and coronal planes (third row).
Visual comparison between the summed image (2a), corre- sponding MVW-PC1 image (2b), arbitrary chosen image of  MVW-PC2 (2c) and MVW-PC3 (2d) Figure 2
Visual comparison between the summed image (2a), 
corresponding MVW-PC1 image (2b), arbitrary cho-
sen image of MVW-PC2 (2c) and MVW-PC3 (2d). 
Notably, the MVW-PC2 and MVW-PC3 images represent 
tissues with two different and uncorrelated tracer pharma-
cokinetics compared to MVW-PC1 images. In MVW-PC2, 
the early pharmacokinetic events are displayed showing the 
parenchymal tracer accumulation in the kidneys. In MVW-
PC3, the pharmacokinetic events are displayed and clearly 
demonstrate the [11C]-MTO characteristic accumulation of 
radioactivity in the gastric juice.BMC Medical Imaging 2009, 9:6 http://www.biomedcentral.com/1471-2342/9/6
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Results
Qualitative comparison
MVW-PCA identified three separate pharmacokinetic
events in the dynamic MTO-PET examinations. The kid-
neys, pancreas, and spleen were clearly delineated in the
MVW-PC2 images corresponding to the early and fast
pharmacokinetic events in these organs. No qualitative
diagnostic information about the depiction of the adren-
ocortical tumours could be retrieved from the MVW-PC2
component. A characteristic feature of [11C]-MTO is the
slow, gradual accumulation of the radioactivity into the
gastric juice. This intermediate pharmacokinetic event was
isolated and displayed in the MVW-PC3 images which,
however, were devoid of diagnostic information related to
visualization of the adrenocortical tumours. MVW-PC1
corresponds to the kinetic with the largest variation and
most predominant behavior of the [11C]-MTO in this
study. This means that MVW-PC1 images contain organs
and tissues with the largest and mostly preserved kinetic
behavior during the whole scanning time. This compo-
nent isolates the pharmacokinetic phase in the dynamic
PET sequence, which best resembled the conventional
summed images based on data 15 to 45 minutes after
[11C]-MTO injection but the image noise was lower and
the organ and tissue separation was better. In these images
the adrenocortical tumours were readily depicted with
qualitatively better lesion delineation than in the
summed images.
Fig. 1, 2 illustrate the qualitative comparison between the
summed image generated by summing the images
through frame 9–14 (15–45 min), and MVW-PC1. For
qualitative comparison, the image color scale minimum
and maximum levels were set to the image minimum and
maximum intensity respectively. The maximum and the
Regression analysis of the SUVs obtained using the "hot spot"  method defined in the MVW-PC1 images when plotted  against the SUVs obtained using ROIs defined in the summed  images shown for the adrenocortical adenomas (dots) and  the normal adrenal glands (triangles) Figure 4
Regression analysis of the SUVs obtained using the 
"hot spot" method defined in the MVW-PC1 images 
when plotted against the SUVs obtained using ROIs 
defined in the summed images shown for the adreno-
cortical adenomas (dots) and the normal adrenal 
glands (triangles).
Table 2: Parameters obtained when performing regression analysis of the SUVs obtained using the "hot spot" method defined in the 
MVW-PC1 images vs. the SUVs obtained using ROIs defined in the summed images.
Question Parameters value
Best fit value Slope 0.9972 ± 0.001907
Best fit value 1/slope 1.003
95% Confidence Intervals Slope 0.9931 to 1.001
Is slope significantly non-zero? T 523
Is slope significantly non-zero? DF 13.00
Is slope significantly non-zero? P Value <0.0001
Is slope significantly non-zero? Deviation from zero? Significant
Bar chart showing the SUV of a normal adrenal gland (upper  chart) and an adrenocortical adenoma (lower chart) for each  patient as obtained by using the "hot spot" method defined in  both the summed and MVW-PC1 image in the MTO-PET  examination in the untreated and treated state Figure 3
Bar chart showing the SUV of a normal adrenal gland 
(upper chart) and an adrenocortical adenoma (lower 
chart) for each patient as obtained by using the "hot 
spot" method defined in both the summed and 
MVW-PC1 image in the MTO-PET examination in 
the untreated and treated state.BMC Medical Imaging 2009, 9:6 http://www.biomedcentral.com/1471-2342/9/6
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minimum intensity were calculated from a ROI situated
on the object in the image not the background.
Quantitative comparison
"Hot spot" method
When the "hot spot" method was used, the coordinates
for the pixels with the highest signal in the MVW-PC1
images differed somewhat from those in the summed
images (Fig. 3, Table 1). It was observed that the SUV
value obtained from the adrenal adenoma from all
patients was higher compared to normal adrenal when
using these methods. The study on linear regression
showed that the correlation between the measurements
when using the two different methods, was high (Fig 4,
Table 2).
Time activity curves
The TACs obtained from ROIs representing adrenocortical
tumours and normal adrenals demonstrated both higher
mean SUVs in the untreated states than in the treated states.
This was true both when MVW-PC1 was used and when the
ROIs were defined in the summed images (Fig 5).
The magnitude of the mean SUV in the adrenal was higher
in the untreated state than in the treated state for ROIs
defined by using both the summed and the MVC-PC1
images (Fig. 6 and Table 3). Similarly, the magnitude of
the mean SUV in the adrenocortical adenomas was higher
in the untreated state than in the treated state for ROIs
defined by using both the summed and the MVC-PC1
images (Fig. 6 and Table 4).
Discussion
PCA has mostly been used for statistical analysis, data
reduction and improvement of image quality of clinical
PET examinations such as in the study by Pavlopoulos et
al. [19]. However, these approaches are not similar to the
method we used here. In our previous studies [16,17], we
demonstrated that by removing the background pixels,
which contained only noise, from the image field, and by
performing noise pre-normalization in conjunction with
volume wise application of PCA (MVW-PCA) on a pre-
processed dataset, the performance of the PCA was
improved. Therefore, the aim here was to apply the intro-
duced MVW-PCA approach to MTO-PET examinations to
obtain diagnostic information from the whole dataset.
Previous analyses on the metabolite spectrum in plasma
have indicated rather complex conditions with a rapid
metabolism of [11C]-MTO, leading to a dominance of
metabolites in protein-free plasma, but with intact tracer
bound to plasma proteins. Therefore, with a simplified
approach of using a standardized summation of the image
data, there is a risk that the pharmacokinetic pattern of the
individual patient is ignored and potential diagnostic
information may be missed.
Table 3: Results obtained from applying a paired t-test on the mean SUVs calculated from ROIs (50% cut-off method) representing 
adrenocortical adenomas and normal adrenal glands defined in MVW-PC1 and summed images, respectively.
Comparison Significant
(P < 0.001)
Mean difference
Untreated vs. treated, MVW-PC1, normal Yes 2.3
Untreated vs. treated, SUM, normal No 1.054
Untreated vs. treated MVW-PCA, adenoma Yes 1.503
Untreated vs. treated, SUM, adenoma No 1.272
Mean TACs of all patients (error bars have been omitted for  clarity), demonstrating the pharmacokinetic behavior of  [11C]-MTO in the adrenocortical adenomas and normal  adrenal glands before and after cortisone treatment, repre- sented by defined ROIs using the 50% cut-off method in the  MVW-PCA images and summed images Figure 5
Mean TACs of all patients (error bars have been 
omitted for clarity), demonstrating the pharmacoki-
netic behavior of [11C]-MTO in the adrenocortical 
adenomas and normal adrenal glands before and 
after cortisone treatment, represented by defined 
ROIs using the 50% cut-off method in the MVW-PCA 
images and summed images.BMC Medical Imaging 2009, 9:6 http://www.biomedcentral.com/1471-2342/9/6
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For several PET tracers used in our department, including
MTO, these time frames, 15–45 minutes, are typically
summed to achieve the highest possible tumour-to-nor-
mal-tissue contrast ratio and the lowest possible image
noise [8]. Compared to these summed images, MVW-PCA
was not able to retrieve additional diagnostic information
from the earlier and later phase of the MTO-PET examina-
tions. By contrast, the MVW-PCA created images with
improved quality and visualization of both the adreno-
cortical tumours and the normal adrenals (Fig. 1, 2). This
was merely based on our visual comparison where the
anatomical details and the image noise were assessed. The
improvement in image quality is also likely to facilitate
the delineation of adrenal lesions and thereby increase the
precision by which ROIs are manually drawn, especially
when investigating smaller tumours. Thus, MVW-PCA
generates several components with various pharmacoki-
netic phases of the administered tracer, implying that
among different adrenal tumours there may be discrepant
pharmacokinetic behavior leading to easier detection and
delineation in separate MVW-PCs.
In our PET examinations, MVW-PCA was applied to
images reconstructed by using FBP. For decades, datasets
reconstructed by FBP have formed the basis for quantita-
tive assessment in PET research. Therefore, FBP recon-
structed datasets were chosen for the initial evaluation of
MVW-PCA on dynamic MTO-PET examinations, rather
the Ordered Subset Expectation Maximization (OSEM)
algorithm [20].
The high correlation between SUVs of the "hot-spot" ROIs
defined in the summed images and those retrieved in the
MVW-PC1 component indicates that the MVW-PCA tech-
nique does not introduce unexpected errors into the
measurements (Fig. 4).
The results of the PET measurements by the "hot spot"
ROIs (4 pixels) method were somewhat different when
MVW-PCA was used compared to the summed images
(Fig. 3). In several patients the coordinates of the pixels
with the highest radioactivity concentration values in
MVW-PC1 were shifted one pixel compared to the
summed images. The number of pixels with the highest
values was 5 or 6 instead of 4 due to the decreased magni-
tude of the noise in the MVW-PC1 images. The decrease of
noise creates a lower difference of values between the
neighbor pixels in MVW-PC1 images. When analyzing the
summed images the pixel values are summed without cor-
recting for the noise magnitude. However, these differ-
ences were not statistically significant.
By contrast, the TACs, i.e., 50% cut-off method (Fig. 5) of
normal adrenal glands and adrenal adenomas derived
from ROIs outlined in the MVW-PC1 images demon-
strated a significantly higher mean SUV than those based
on the summed images, being verified in both the exami-
nations performed before and after cortisone treatment.
Thus, the application of MVW-PCA leads to improved pre-
cision in defining the ROIs since pixels with the highest
Bar chart shows the mean SUVs of 7 patients calculated in  ROIs representing the adrenocortical adenomas and normal  adrenal glands Figure 6
Bar chart shows the mean SUVs of 7 patients calcu-
lated in ROIs representing the adrenocortical adeno-
mas and normal adrenal glands. The means are defined 
in both the summed and MVW-PC1 images, using the 50% 
cut-off method before and after cortisone treatment.
Table 4: Results obtained from applying a two-tailed t-test on the mean difference in percent of SUVs calculated from ROIs (50% cut-
off method) representing adrenocortical adenomas and normal adrenal glands defined in MVW-PC1 and summed images, 
respectively.
Comparison P value Mean ± SEM of MVW-PC1, SUM
MVW-PC1, adenoma,% vs SUM, adenoma,% 0.2906 12.78 ± 1.258, 10.90 ± 1.213
MVW-PC1, normal,% vs SUM, normal,% 0.0002 22.59 ± 1.711, 11.91 ± 1.731BMC Medical Imaging 2009, 9:6 http://www.biomedcentral.com/1471-2342/9/6
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radioactivity concentration are included. The statistical
analysis using repeated measures ANOVA (50% cut-off)
showed significant differences between treated and
untreated adrenocortical adenomas and normal adrenal
glands when the MVW-PC1 was used whereas the
summed images did not. Thus, MVW-PC1 images may
provide a higher level of confidence in the statistical data
in clinical trials in which PET measurements are used.
Theoretically, by using MVW-PCA, either alternatively or
concurrently, it may be possible to achieve the same sta-
tistical power, while reducing the number of patients in
the trial. This must, however, be further evaluated.
A limitation with this study is the small number of
patients in whom no dramatic impact was shown on the
precision of the PET measurements by applying MVW-
PCA. Moreover, in this first study applying MVW-PCA on
PET of organs other than the brain, merely FBP was used.
In future, work should also include automation of this
method and MVW-PCA should be applied to PET exami-
nations reconstructed by the OSEM method. Similarly,
the output of the ROI analysis, including graphical illus-
trations, may be generated and illustrated automatically.
The ongoing trend in PET tracer development to replace
tracers with short half-lives, such as11C tracers, with longer
lived tracers also includes the currently studied [11C]-MTO
with 18F-labeled analogs presently being developed. These
analogs will provide more time for the tracer to accumu-
late in adrenocortical tumours as well as be eliminated
from normal tissues. However, the radiation dose to the
patient will be higher than for [11C]-MTO, which is
approximately 3 mSv.
Conclusion
In conclusion, MVW-PCA applied on FPB reconstructed
dynamic PET examinations of patients with small adreno-
cortcal adenomas improved the image quality by decreas-
ing the image noise and increased the precision by which
the ROIs were defined for PET measurements. The
decrease in tracer accumulation induced by cortisone
treatment was more evident in the TAC analysis when
MVW-PCA was used as compared to when ROIs were
defined in the conventionally summed images.
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